India, Nov. 3 -- Nucelion Therapeutics, a newly established, Hyderabad-based Contract Research Development and Manufacturing Organisation (CRDMO) focused on cell and gene therapies, has announced its formal launch: Nucelion, a wholly owned subsidiary of Bharat Biotech International Ltd.

The CRDMO aims to support global life science innovators with high-quality, scalable process development and manufacturing solutions for advanced therapies, indicated for cancers, autoimmune disorders, and rare genetic disorders.

The future of pharmaceutical innovation will be biological, with new modalities expected to drive a large share of growth worldwide. Within this shift, cell therapies-autologous, allogeneic, and emerging in vivo approaches-are p...